Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05385484
Other study ID # 849897
Secondary ID 1R01HD103563-01A
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 18, 2022
Est. completion date June 2025

Study information

Verified date January 2024
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized control trial will test an economic intervention to reduce Kenyan men's engagement in behaviors that increase the risk of HIV/STIs. Participants randomized to the intervention group will be able to open accounts with a partner bank and will be incentivized to save with lottery-based rewards.


Description:

This project will evaluate an innovative, theoretically-motivated economic intervention to reduce men's engagement in transactional sex and other risky behaviors. Leveraging innovations in mobile financial services and research on savings behavior in low-income countries, the investigators propose to test an intervention that seeks to motivate high-risk, income-earning men in western Kenya to reduce their spending on risky behaviors and instead save their disposable income in local bank accounts. These bank accounts will include additional incentives to save in the form of lottery-based rewards linked to amounts saved. The intervention will also encourage participants to develop savings goals and strategies, and provide periodic reminders about saving regularly. Through a direct economic mechanism (incentives to shift expenditures from the present to the future) and a psychological mechanism (increasing future orientation), the investigators hypothesize that the intervention will result in increased savings, reduced spending on transactional sex and alcohol, less risky sexual behavior, and reduced risk of HIV and sexually transmitted infections (STIs). The investigators will conduct a randomized controlled trial among men who are at high risk of HIV and STI infection and determine the effects of a savings intervention on health and economic outcomes. Specific aims of the project are as follows. Aim 1: Determine the impact of the intervention on savings and investment behavior, self-reported sexual behavior, and incidence of HIV/STIs. Aim 2: Quantitatively and qualitatively assess mechanisms of behavior change among participants and a sample of their female partners.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1500
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria: - Male - Age 18-39 years - Resides in study community and plans to remain for the next 2 years - Used alcohol or other substances in the past month - Engagement in any transactional sex (defined as payment of money, goods, or services in exchange for sex) in the past 3 months - Has a steady income source that typically results in earnings every week - Owns mobile phone - Already has or is willing to open an account with partner banking institution - Has national identification card (required for opening bank account) - Has Kenya Revenue Authority personal identification number or is willing to create one (required for opening bank account) Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Receives mobile banking account with incentives to save
Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.

Locations

Country Name City State
Kenya Impact Research and Development Organization Kisumu

Sponsors (6)

Lead Sponsor Collaborator
University of Pennsylvania Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Impact Research & Development Organization, RTI International, University of California, San Francisco, University of Washington

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of HIV and other STIs Composite incidence of at least one of HIV or other STIs (herpes simplex virus type 2 (HSV-2), Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT)) over 24 months. The investigators will combine all STIs (including HIV) into a composite variable, with each participant counting once. For participants who are HIV-positive at baseline or HSV-2-positive, the outcome will be defined over all STIs other than HIV. 24 months
Secondary Expenditures on alcohol Money spent on alcohol. 6 month intervals
Secondary Expenditures on transactional sex Money, goods, and services spent on transactional sex (defined broadly to include financial and non-financial transfers to commercial and non-commercial sexual partners). 6 month intervals
Secondary Expenditures on gambling Money spent on gambling. 6 month intervals
Secondary Number of sexual partners Number of sexual partners participant had in the past 3 months. 6 month intervals
Secondary Recent engagement in transactional sex Whether participant engaged in transactional sex (defined broadly to include financial and non-financial transfers to commercial and non-commercial sexual partners), or not in the past 3 months. 6 month intervals
Secondary Number of transactional sex partners Total number of transactional sex partners participant had in the past 3 months. 6 month intervals
Secondary Number of transactional sex encounters Number of transactional sex encounters participant engaged in during the past 3 months. 6 month intervals
Secondary Condom use at most recent sexual encounter Whether participant used a condom or not at most recent sexual encounter in the past 3 months. 6 month intervals
Secondary Alcohol use As measured by the Alcohol Use Disorders Identification Test-Concise (AUDIT-C) scale. The AUDIT-C is scored on a scale of 0-12, and higher values mean worse outcomes 6 month intervals
Secondary HIV, CT, and NG incidence between 0-12 months and 12-24 months More temporally granular measures of incidence for HIV, CT, and NG. Up to 24 months
Secondary Engagement in care among those who are HIV-positive Whether or not participants who are HIV-positive are currently engaged in care for their HIV. 6 month intervals
Secondary Expenditures on food Money spent on food items. 6 month intervals
Secondary Expenditures on household needs Money spent on household needs (e.g., utilities). 6 month intervals
Secondary Savings and investment Total savings and investment, defined as the money value of formal and informal savings as well as investments in physical and human capital. 6 month intervals
Secondary Total formal savings The sum of savings balances in all formal bank accounts. 6 month intervals
Secondary Total household assets Value of all assets. 6 month intervals
Secondary Expenditure on human capital investment Money spent on human capital investment (e.g., spending on children's education). 6 month intervals
Secondary Expenditure on productive assets Money spent on productive assets (e.g., spending on agricultural equipment). 6 month intervals
Secondary Expenditure on housing improvement Money spent on structure of dwelling. 6 month intervals
See also
  Status Clinical Trial Phase
Terminated NCT03516318 - Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria N/A
Completed NCT04653194 - Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Phase 3
Completed NCT01792570 - DRV/r + RPV QD: Efficacy and Toxicity Reduction Phase 3
Active, not recruiting NCT04826562 - Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Phase 4
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Completed NCT02812329 - Intervention to Encourage HIV Testing and Counseling Among Adolescents Phase 1
Completed NCT02919306 - Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Phase 1/Phase 2
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study Phase 1/Phase 2
Recruiting NCT01778374 - Mater-Bronx Rapid HIV Testing Project. N/A
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT01490346 - Tissue Drug Levels of HIV Medications N/A
Completed NCT01076179 - Kaletra in Combination With Antiretroviral Agents N/A
Completed NCT01460433 - Problems With Immune Recovery in the Gut Tissue N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Terminated NCT04240210 - Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Phase 4
Active, not recruiting NCT04704336 - Integration of Hypertension Management Into HIV Care in Nigeria N/A
Completed NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study Phase 1